Vericel Co. (NASDAQ:VCEL) Position Lessened by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 11.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 96,371 shares of the biotechnology company's stock after selling 12,375 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.20% of Vericel worth $4,072,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. CWM LLC boosted its stake in Vericel by 319.0% during the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 504 shares during the last quarter. SG Americas Securities LLC increased its position in Vericel by 7.0% in the second quarter. SG Americas Securities LLC now owns 11,881 shares of the biotechnology company's stock worth $545,000 after purchasing an additional 779 shares during the last quarter. Nisa Investment Advisors LLC grew its position in Vericel by 9.7% in the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company's stock worth $114,000 after acquiring an additional 220 shares in the last quarter. Summit Global Investments purchased a new stake in Vericel in the 2nd quarter worth about $465,000. Finally, Louisiana State Employees Retirement System lifted its holdings in Vericel by 3.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 24,500 shares of the biotechnology company's stock valued at $1,124,000 after buying an additional 900 shares in the last quarter.

Vericel Stock Performance

NASDAQ VCEL traded up $0.46 during trading hours on Friday, hitting $57.47. 307,282 shares of the company's stock were exchanged, compared to its average volume of 426,312. The firm has a market capitalization of $2.84 billion, a P/E ratio of 948.49 and a beta of 1.71. Vericel Co. has a 12-month low of $32.31 and a 12-month high of $61.49. The business's 50 day moving average is $49.95 and its 200-day moving average is $47.87.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. As a group, equities research analysts anticipate that Vericel Co. will post 0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on VCEL. BTIG Research lifted their price objective on shares of Vericel from $56.00 to $66.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. TD Cowen raised their price target on shares of Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, August 27th. StockNews.com cut Vericel from a "hold" rating to a "sell" rating in a report on Thursday. HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. Finally, Stephens raised Vericel to a "strong-buy" rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $59.71.

Insider Transactions at Vericel

In other Vericel news, Director Paul K. Wotton sold 2,600 shares of Vericel stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $58.72, for a total value of $152,672.00. Following the transaction, the director now owns 27,402 shares in the company, valued at approximately $1,609,045.44. The trade was a 8.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at $443,850. The trade was a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,266 shares of company stock worth $2,090,636. Insiders own 5.20% of the company's stock.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.